CADL241220C12000
- 0.35
- -0.10-22.22%
Candel Therapeutics Newsroom
H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $11
Candel Therapeutics Advances in Cancer Trials Amid Financial Challenges
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $11 Price Target
Candel Therapeutics Analyst Ratings
Promising Potential of Candel Therapeutics' CAN-2409 Drives Buy Rating
Diakonos Oncology Appoints Laura Aguilar, M.D., Ph.D. as Chief Medical Officer
Candel Therapeutics CEO Anticipates 'Paradigm Shift' in Prostate Cancer Treatment as Q3 Work Wraps up | NASDAQ:CADL
Candel Therapeutics | 10-Q: Q3 2024 Earnings Report
Earnings Flash (CADL) CANDEL THERAPEUTICS Reports Q3 Loss $-0.33 Per Share
Candel Therapeutics | 8-K: Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Express News | Candel Therapeutics: On Track for Phase 2B & Phase 3 Topline Data in Non-Metastatic, Localized Prostate Cancer for Can-2409 in Q4
Candel Therapeutics: Runway To Fund Current Operating Plan to End of 1Q 2025 >CADL
Express News | Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Express News | Candel Therapeutics Q3 Basic EPS USD -0.33
Express News | Candel Therapeutics Q3 Income From Operations USD -8.757 Million
Express News | Candel Therapeutics Q3 Net Income USD -10.646 Million
Press Release: Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Candel Therapeutics Advances in Cancer Treatment Trials
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
Candel Therapeutics Poised for Breakthrough in Cancer Therapies, Key Trials to Read Out by Year-End | NASDAQ:CADL